Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study (Q43924146)
Jump to navigation
Jump to search
scientific article published on 21 September 2017
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study |
scientific article published on 21 September 2017 |
Statements
1 reference
Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study (English)
1 reference
Irit Avivi
1 reference
Pieternella Lugtenburg
1 reference
Henriette Berenschot
1 reference
Osman Ilhan
1 reference
Jean Pierre Marolleau
1 reference
Arnon Nagler
1 reference
Antonio Rueda
1 reference
Monica Tani
1 reference
Mehmet Turgut
1 reference
Stuart Osborne
1 reference
Rodney Smith
1 reference
21 September 2017
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference